BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $21.7778.

BCRX has been the topic of a number of analyst reports. Royal Bank Of Canada lifted their price target on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Wedbush dropped their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald increased their target price on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $77,000. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares in the last quarter. Envestnet Portfolio Solutions Inc. acquired a new position in BioCryst Pharmaceuticals in the 4th quarter valued at approximately $81,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in BioCryst Pharmaceuticals in the 3rd quarter valued at approximately $81,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Up 1.1%

BCRX opened at $11.11 on Thursday. The firm has a market cap of $2.82 billion, a PE ratio of -6.24 and a beta of 0.55. The business has a fifty day simple moving average of $9.07 and a 200-day simple moving average of $8.41. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.19.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The company had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. During the same period last year, the firm earned $0.20 earnings per share. The firm’s revenue for the quarter was up 7.5% on a year-over-year basis. On average, equities research analysts anticipate that BioCryst Pharmaceuticals will post -2.63 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.